首页> 外文OA文献 >Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients†
【2h】

Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients†

机译:成人颅内世卫组织II级室间隔膜瘤:一系列114例患者的长期结果和预后因素分析†

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ependymomas account for 2% of all intracranial tumors in adults. Considerable controversy continues to exist with regard to their prognostic factors and therapeutic management due to the rarity and the heterogeneity of series reported so far. The authors report a retrospective study of a homogenous population of 114 adult patients harboring WHO grade II intracranial ependymomas from 32 French Neurosurgical Centers between 1990 and 2004. All clinico-radiological and follow-up data were analyzed, and a central pathologic review was performed by two confirmed neuropathologists. The 5- and 10-year overall survival (OS) rates were 86.1% and 81.0%, respectively; the 5- and 10-year progression-free survival (PFS) rates were 74.6% and 58.9%, respectively. On multivariate analysis, the OS rates were associated with preoperative KPS score (P = .027), extent of surgery (P = .008), and tumor location (supratentorial vs infratentorial, P = .012). The multivariate analysis also revealed that the risk of recurrence was associated with incomplete resection (P = .001) and supratentotrial location (P = .038). Moreover, adjuvant radiotherapy (RT) for patients with incompletely resected tumors is responsible for a significant improvement of both overall (P = .005) and progression-free (P = .002) survival. This study clearly supports the major prognostic impact of the extent of surgery in WHO grade II. Interestingly, tumor location also seems to have an actual impact on both OS and PFS. Finally, the prognostic impact of RT was found to be beneficial for incompletely resected tumors.
机译:室间隔瘤占成人颅内肿瘤总数的2%。由于迄今为止报道的系列药物的稀有性和异质性,关于它们的预后因素和治疗管理仍存在相当多的争议。作者报告了一项回顾性研究,研究对象是1990年至2004年间来自32个法国神经外科中心的114例具有WHO II级颅内室间隔膜瘤的成年患者的同质人群。分析了所有临床放射学和随访数据,并由两名确诊的神经病理学家。 5年和10年总生存率分别为86.1%和81.0%。 5年和10年无进展生存率(PFS)分别为74.6%和58.9%。在多变量分析中,OS率与术前KPS评分(P = .027),手术范围(P = .008)和肿瘤位置(幕上与下腹,P = .012)相关。多元分析还显示,复发风险与不完全切除(P = .001)和上睑位置(P = .038)有关。此外,对于未完全切除的肿瘤患者,辅助放疗(RT)可以显着改善总体生存率(P = .005)和无进展生存期(P = .002)。这项研究清楚地支持了世卫组织II级手术范围的主要预后影响。有趣的是,肿瘤的位置似乎也对OS和PFS都有实际影响。最后,发现RT的预后影响对不完全切除的肿瘤是有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号